Thromb Haemost 1983; 50(02): 552-556
DOI: 10.1055/s-0038-1665253
Original Article
Schattauer GmbH Stuttgart

T-Cell Alterations in Hemophiliacs Treated with Commercial Clotting Factor Concentrates

Authors

  • K Lechner

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • H Niessner

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • P Bettelheim

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • E Deutsch

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • I Fasching

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • M Fuhrmann

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • W Hinterberger

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • C Korninger

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • E Neumann

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • K Liszka

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • W Knapp

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • W R Mayr

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • G Stingl

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
  • U Zeitlhuber

    The Division of Hematology and Blood Coagulation, First Department of Medicine; Institute of Immunology; Institute of Blood Group Serology; Department of Dermatology and Department of Pediatrics, University of Vienna, Austria
Further Information

Publication History

Received 25 April 1983

Accepted 01 June 1983

Publication Date:
18 July 2018 (online)

Preview

Summary

Various immunological parameters were determined in 46 patients with severe hemophilia A and in 9 patients with severe hemophilia B. All patients were treated over many years with commercial factor VIII or IX concentrates. Patients with severe classic hemophilia had a significantly reduced relative and absolute number of T-helper cells and a significantly increased relative and absolute number of T-suppressor cells. About half of these patients had an inverse T-helper/suppressor cell ratio. Patients with moderate hemophilia A and severe hemophilia B did not show these abnormalities. Hemophiliacs with an inverse ratio had a significantly higher concentration of serum total protein, IgG and IgM. No relationship between the amount of factor VIII concentrate administered, the HLA-type of the patient, the presence or absence of CMV-antibodies, hepatitis markers, thrombocytopenia and abnormal liver function tests to the T-cell abnormalities could be established. Lymphadenopathy was frequently associated with an inverse ratio. Indirect evidence suggests that the alterations of the immune system began in 1979/80.